The estimated Net Worth of Daniel H Zimmerman is at least $1.5 Milhão dollars as of 26 February 2020. Daniel Zimmerman owns over 923 units of Cel-Sci stock worth over $134,977 and over the last 21 years he sold CVM stock worth over $82,909. In addition, he makes $1,283,340 as Senior Vice President - Research e Cellular Immunology at Cel-Sci.
Daniel has made over 8 trades of the Cel-Sci stock since 2003, according to the Form 4 filled with the SEC. Most recently he bought 923 units of CVM stock worth $9,996 on 26 February 2020.
The largest trade he's ever made was selling 42,000 units of Cel-Sci stock on 2 October 2007 worth over $26,460. On average, Daniel trades about 956 units every 53 days since 2003. As of 26 February 2020 he still owns at least 114,387 units of Cel-Sci stock.
You can see the complete history of Daniel Zimmerman stock trades at the bottom of the page.
Dr. Daniel H. Zimmerman Ph.D. serves as Senior Vice President - Research, Cellular Immunology of the Company. He joined CEL-SCI in January 1996 as the Vice President of Research, Cellular Immunology. Dr. Zimmerman founded CELL-MED, Inc. and was its president from 1987-1995. From 1973-1987, Dr. Zimmerman served in various positions at Electronucleonics, Inc. His positions included: Scientist, Senior Scientist, Technical Director and Program Manager. Dr. Zimmerman held various teaching positions at Montgomery College between 1987 and 1995. Dr. Zimmerman has invented technologies which are covered by over a dozen US patents as well as many foreign equivalent patents. He is the author of over 40 scientific publications in the area of immunology and infectious diseases. He has been awarded numerous grants from NIH and DOD. From 1969-1973, Dr. Zimmerman was a Senior Staff Fellow at NIH. For the following 25 years, he continued on at NIH as a guest worker. Dr. Zimmerman received a Ph.D. in Biochemistry in 1969, and a Masters in Zoology in 1966 from the University of Florida as well as a B.S. in Biology from Emory and Henry College in 1963.
As the Senior Vice President - Research e Cellular Immunology of Cel-Sci, the total compensation of Daniel Zimmerman at Cel-Sci is $1,283,340. There are 3 executives at Cel-Sci getting paid more, with Geert Kersten having the highest compensation of $4,546,360.
Daniel Zimmerman is 79, he's been the Senior Vice President - Research e Cellular Immunology of Cel-Sci since 2009. There are 1 older and 11 younger executives at Cel-Sci. The oldest executive at Cel-Sci Corp. is Dr. Daniel H. Zimmerman Ph.D., 80, who is the Sr. VP of Research & Cellular Immunology.
Daniel's mailing address filed with the SEC is 8229 BOONE BLVD, STE 802, VIENNA, VA, 22182.
Over the last 21 years, insiders at Cel-Sci have traded over $3,069,559 worth of Cel-Sci stock and bought 1,693,350 units worth $1,328,136 . The most active insiders traders include Clara Maximilian De, Geert R Kersten, eEyal Talor. On average, Cel-Sci executives and independent directors trade stock every 50 days with the average trade being worth of $42,938. The most recent stock trade was executed by Robert Eugene Watson on 8 May 2024, trading 20,000 units of CVM stock currently worth $27,800.
cel-sci corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. the company's lead investigational immunotherapy is multikine, which is under phase iii clinical trial for the treatment of head and neck cancer. its ligand epitope antigen presentation system (leaps), a pre-clinical patented t-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. the company also develops leaps-h1n1-dc; cel-2000 and cel-4000 are product candidates for the treatment of rheumatoid arthritis; and leaps cov-19, a product candidate to treat covid-19 coronavirus. cel-sci corporation has a collaboration agreement with the university of georgia's center for vaccines and immunology to develop leaps covid-19 immunotherapy. the company was founded in 1983 and is headquartered in vienna, virginia.
Cel-Sci executives and other stock owners filed with the SEC include: